Abstract
Tyrosinemia type I is a genetic disorder characterized by accumulation in the blood and urine of the toxic metabolite succinylacetone (SUAC), not detectable in healthy samples. In many countries, newborns are screened for tyrosinemia type I using tyrosine as a primary marker. Unfortunately, tyrosine accumulation may take longer to occur and it may be not obvious when specimens are collected, in the first few days of life, as for newborn screening. In 2008, we reported changes to simultaneously measure acylcarnitines, amino acids, and SUAC during expanded newborn screening. We established the usefulness of this method after identifying a first asymptomatic newborn affected by tyrosinemia type I. Now we report a second infant with positive SUAC screening result (14.1 μmol/L, n.v. < 2) and normal tyrosine concentration (74 μmol/L; n.v. < 250). We also performed molecular analysis of FAH gene in both patients after diagnosis at newborn screening. They had consanguineous parents and were both homozygous for two known disease-causing mutations of the FAH gene. The outcome of patients detected in the MS/MS screening is significantly favorable. We also report our results of newborn screening for tyrosinemia type I before and after inclusion of SUAC as a primary marker for this disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adam BW, Lim TH, Hall EM, Hannon WH (2009) Preliminary proficiency testing results for succinylacetone in dried blood spots for newborn screening for tyrosinemia type I. Clin Chem 55:2207–2213
Al-Dirbashi OY, Rashed MS, Jacob M, Al-Ahaideb LY, Al-Amoudi M, Rahbeeni Z, Al-Sayed MM et al (2008) Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type I using UPLC-MS/MS. Biomed Chromatogr 22:1181–1185
Al-Gazali L, Hamamy H, Al-Arrayad S (2006) Genetic disorders in the Arab world. BMJ 333:831–834
Allard P, Grenier A, Korson MS, Zytkovicz TH (2004) Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 37:1010–1015
Arranz JA, Piñol F, Kozak L, Pérez-Cerdà C, Cormand B, Ugarte M, Riudor E (2002) Splicing mutations, mainly IVS6–1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients. Hum Mutat 20:180–188
Jaouad IC, Elalaoui SC, Sbiti A, Elkerh F, Belmahi L, Sefiani A (2009) Consanguineous marriages in Morocco and the consequence for the incidence of autosomal recessive disorders. J Biosoc Sci 41:575–581
Joshi SN, Venugopalan P (2004) Experience with NTBC therapy in hereditary tyrosinemia type I: an alternative to liver transplantation. Ann Trop Paediatr 24:259–265
la Marca G, Malvagia S, Pasquini E, Innocenti M, Fernandez MR, Donati MA, Zammarchi E (2008) The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs. Rapid Commun Mass Spectrom 22:812–818
la Marca G, Malvagia S, Funghini S, Pasquini E, Moneti G, Guerrini R, Zammarchi E (2009) The successful inclusion of succinylacetone as a marker of tyrosinemia type I in Tuscany newborn screening program. Rapid Commun Mass Spectrom 23:3891–3893
Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340:813–817
Mitchell GA, Grope M, Lambert M, Tanguay RM (2001) Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 1777–1805
Ploos van Amstel JK, Bergman AJ, van Beurden EA, Roijers JF, Peelen T, van den Berg IE, Poll-The BT, Kvittingen EA, Berger R (1996) Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship.Hum Genet 97:51–59
Rootwelt H, Høie K, Berger R, Kvittingen EA (1996) Fumarylacetoacetase mutations in tyrosinaemia type I. Hum Mutat 7:239–243
Sander J, Janzen N, Peter M, Sander S, Steuerwald U, Holtkamp U, Schwahn B et al (2006) Newborn screening for hepatorenal tyrosinemia: tandem mass spectrometric quantification of succinylacetone. Clin Chem 52:482–487
Turgeon C, Magera MJ, Allard P, Tortorelli S, Gavrilov D, Oglesbee D, Raymond K et al (2008) Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Clin Chem 54:657–664
US Department of Health and Human Services, Maternal and Child Health Bureau (2005) Newborn screening: toward a uniform screening panel and system report for public comment. Fed Regist 70:308–329
Wilcken B, Wiley V, Hammond J, Carpenter K (2003) Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 348:2304–2312
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Synopsis
Synopsis
Succinylacetone determination on dried blood spot.
Rights and permissions
Copyright information
© 2011 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
la Marca, G. et al. (2011). Newborn Screening for Tyrosinemia Type I: Further Evidence that Succinylacetone Determination on Blood Spot Is Essential. In: JIMD Reports - Case and Research Reports, 2011/1. JIMD Reports, vol 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2011_24
Download citation
DOI: https://doi.org/10.1007/8904_2011_24
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-17707-1
Online ISBN: 978-3-642-17708-8
eBook Packages: MedicineMedicine (R0)